MA33758B1 - Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes - Google Patents

Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes

Info

Publication number
MA33758B1
MA33758B1 MA34878A MA34878A MA33758B1 MA 33758 B1 MA33758 B1 MA 33758B1 MA 34878 A MA34878 A MA 34878A MA 34878 A MA34878 A MA 34878A MA 33758 B1 MA33758 B1 MA 33758B1
Authority
MA
Morocco
Prior art keywords
antagonists
antibody
tnfr1
stable anti
polypeptides
Prior art date
Application number
MA34878A
Other languages
Arabic (ar)
English (en)
Inventor
Silva Inusha De
Armin Sepp
Adriaan Allart Stoop
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33758(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA33758B1 publication Critical patent/MA33758B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne des domaines variables uniques de l'anticorps anti-TNFR1 stable à l'entreposage (d Abs), des antagonistes et des ligands multispécifiques, ainsi que des méthodes et des utilisations de ceux-ci. Les polypeptides anti-TNFR1, les domaines variables uniques de l'anticorps (d Abs), les antagonistes et les ligands multispécifiques sont utiles pour le traitement et/ou la prévention d'une maladie inflammatoire, telle que la BPCO, ainsi que pour l'administration par voie pulmonaire ou orale ou l'acheminement au poumon ou au tractus gastro-intestinal.
MA34878A 2009-10-27 2012-05-18 Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes MA33758B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25523509P 2009-10-27 2009-10-27
PCT/EP2010/066046 WO2011051217A1 (fr) 2009-10-27 2010-10-25 Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes

Publications (1)

Publication Number Publication Date
MA33758B1 true MA33758B1 (fr) 2012-11-01

Family

ID=43382391

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34878A MA33758B1 (fr) 2009-10-27 2012-05-18 Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes

Country Status (26)

Country Link
US (1) US20150210767A1 (fr)
EP (1) EP2493504B1 (fr)
JP (1) JP2013507978A (fr)
KR (1) KR20120101417A (fr)
CN (1) CN102686239B (fr)
AR (1) AR078763A1 (fr)
AU (1) AU2010311640B2 (fr)
BR (1) BR112012010114A2 (fr)
CA (1) CA2777312A1 (fr)
CL (1) CL2012001055A1 (fr)
CO (1) CO6612254A2 (fr)
CR (1) CR20120197A (fr)
DO (1) DOP2012000113A (fr)
EA (1) EA022898B1 (fr)
ES (1) ES2552177T3 (fr)
IL (1) IL218860A0 (fr)
MA (1) MA33758B1 (fr)
MX (1) MX2012005024A (fr)
NZ (1) NZ599114A (fr)
PE (1) PE20121564A1 (fr)
SG (1) SG10201500274TA (fr)
TW (1) TW201125877A (fr)
UA (1) UA107200C2 (fr)
UY (1) UY32969A (fr)
WO (1) WO2011051217A1 (fr)
ZA (1) ZA201203052B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102405236A (zh) * 2009-02-19 2012-04-04 葛兰素集团有限公司 改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂
EP2721066A1 (fr) * 2011-06-17 2014-04-23 Glaxo Group Limited Antagonistes du récepteur 1 du facteur de nécrose tumorale
AU2014211438B2 (en) * 2013-01-31 2017-02-02 Glaxo Group Limited Method of producing a protein
WO2015104322A1 (fr) 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Traitement de maladies inflammatoires avec des antagonistes anti-tnfr1 non compétitifs
MA43764A (fr) * 2016-04-05 2021-06-02 Baliopharm Ag Inhibiteur monovalent de l'interaction hutnfr1
WO2022047243A1 (fr) 2020-08-27 2022-03-03 Enosi Life Sciences Corp. Méthodes et compositions pour traiter des maladies auto-immunes et un cancer
WO2022117569A1 (fr) 2020-12-02 2022-06-09 Oncurious Nv Anticorps antagoniste de ccr8 en combinaison avec un anticorps agoniste du récepteur bêta de la lymphotoxine en thérapie contre le cancer
CN114699533B (zh) * 2022-05-06 2023-05-09 郑州大学 一种核酸适配体和多肽交联的双靶点复合核酸纳米药物制备方法与应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
EP1892296A1 (fr) 1988-09-02 2008-02-27 Dyax Corporation Production et sélection de protéines de liaison diversifiées recombinantes
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1994026087A2 (fr) 1993-05-14 1994-11-24 Connor Kim C O Production de proteines de recombinaison, culture de cellules d'insectes et procede s'y rapportant
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
DK1801214T3 (da) 1997-07-07 2011-01-24 Medical Res Council In vitro sorteringsfremgangsmåde
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2399388A1 (fr) 2000-02-11 2001-08-16 Michael J. Lenardo Identification d'un nouveau domaine dans la famille des recepteurs du facteur de necrose tumorale mediant l'assemblage et la fonction du recepteur de pre-ligand
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
WO2003076567A2 (fr) 2002-03-05 2003-09-18 Eli Lilly And Company Proteines hybrides g-csf heterologues
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2004041865A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique stabilises
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
CA2511910A1 (fr) 2002-12-27 2004-07-15 Domantis Limited Ligand
EP2357237A1 (fr) 2003-05-14 2011-08-17 Domantis Limited Un procédé pour obtenir des polypeptides qui se replient d'une manière réversible à partir d'u nrépertoire de polypeptides.
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
EP1729795B1 (fr) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Proteines hybrides d'albumine
CN101084014A (zh) * 2004-10-08 2007-12-05 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CA2688433A1 (fr) 2007-06-06 2008-12-11 Domantis Limited Procede de selection de polypeptides resistant aux proteases
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
MX2011008749A (es) * 2009-02-19 2011-09-06 Glaxo Group Ltd Variantes de union a anti-albumina de suero mejoradas.
CN102405236A (zh) * 2009-02-19 2012-04-04 葛兰素集团有限公司 改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂

Also Published As

Publication number Publication date
CA2777312A1 (fr) 2011-05-05
EA201290172A1 (ru) 2013-04-30
ZA201203052B (en) 2013-09-25
UA107200C2 (uk) 2014-12-10
JP2013507978A (ja) 2013-03-07
DOP2012000113A (es) 2012-08-15
UY32969A (es) 2011-05-31
AU2010311640B2 (en) 2015-01-29
TW201125877A (en) 2011-08-01
MX2012005024A (es) 2012-09-07
NZ599114A (en) 2014-09-26
KR20120101417A (ko) 2012-09-13
CN102686239B (zh) 2016-02-03
AU2010311640A1 (en) 2012-05-10
CN102686239A (zh) 2012-09-19
ES2552177T3 (es) 2015-11-26
EP2493504A1 (fr) 2012-09-05
EP2493504B1 (fr) 2015-10-07
IL218860A0 (en) 2012-06-28
BR112012010114A2 (pt) 2017-08-08
CL2012001055A1 (es) 2012-10-05
US20150210767A1 (en) 2015-07-30
AR078763A1 (es) 2011-11-30
WO2011051217A1 (fr) 2011-05-05
PE20121564A1 (es) 2012-11-29
EA022898B1 (ru) 2016-03-31
CR20120197A (es) 2012-06-22
CO6612254A2 (es) 2013-02-01
SG10201500274TA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
MA33758B1 (fr) Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes
MA31403B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
MA31437B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
MA30337B1 (fr) Anticorps
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA29723B1 (fr) Composes
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
MA31898B1 (fr) Compositions pharmaceutiques
MA33339B1 (fr) Utilisation d'un anticorps anti-tau ps422 pour le traitement de maladies cérébrales
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
UA109633C2 (uk) Антитіло людини проти тканинного фактора
ATE466886T1 (de) Adzyme und deren verwendungen
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
MA33221B1 (fr) Fusions de médicament et conjugués afférents
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
EA201190116A1 (ru) Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
MA47392A1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo